Bart Dunn
About Bart Dunn
Bart Dunn is the Head of Strategy and Corporate Development at Collegium Pharmaceutical, with over 25 years of experience in the life sciences industry, specializing in M&A, licensing, and divestiture transactions.
Title: Head of Strategy and Corporate Development
Bart Dunn serves as the Head of Strategy and Corporate Development at Collegium Pharmaceutical. He joined the company in August 2019, taking on the role of Executive Vice President, Strategy and Corporate Development. His responsibilities include guiding corporate strategy, overseeing development initiatives, and steering the company towards its long-term goals.
Career Experience in Corporate Development
Bart Dunn brings over 25 years of experience in the life sciences industry. Prior to his tenure at Collegium Pharmaceutical, Dunn was the Senior Vice President of Corporate Development at Vivelix Pharmaceuticals. He also served as Vice President of Strategy and Corporate Development at Patheon before it was acquired by Thermo Fisher. He has been instrumental in corporate development and strategy activities at NuPathe Inc, Inspire Pharmaceuticals, and Pfizer.
Significant Transactions Led
Throughout his career, Bart Dunn has been pivotal in over 45 mergers, acquisitions, licensing, and divestiture transactions. These deals have a cumulative value exceeding $12 billion. His extensive experience includes critical roles in transactions that led to NuPathe's acquisition by Teva and Inspire Pharmaceuticals' acquisition by Merck.
Educational Background in Business and Accounting
Bart Dunn is academically grounded with a Master of Business Administration (MBA) from Saint Joseph's University. He also holds a Bachelor of Business Administration (BBA) in Accounting from Pace University. Prior to his corporate development roles, Dunn practiced as a Certified Public Accountant, leveraging his financial expertise in his strategic roles.